Billionaires’ Battle: India’s Race to Revolutionize Weight-Loss Drugs with Affordable Alternatives
In this article (5)
Indian billionaires are vying to introduce cost-effective medications for diabetes and obesity in response to the escalating demand for reasonably priced alternatives to the well-known weight-loss drug, Ozempic. Sun Pharmaceutical Industries, established by billionaire Dilip Shanghvi, has recently released weight-loss pen injections under the Noveltreat and Sematrinity brands.
Competitive Pricing
Priced at approximately INR3,600 (US$38.3) per month for the lowest dose, Noveltreat competes directly with higher-priced options. Sematrinity offers a similarly affordable alternative at INR3,000 monthly, less than half the cost of Ozempic and Wegovy, notable weight-control medications manufactured by the Denmark-based company, Novo Nordisk.
Kirti Ganorkar, Sun Pharmaceutical’s Managing Director stated, “With the launch of Noveltreat and Sematrinity, we are striving to offer a high-quality, cost-effective therapy to a broader patient demographic in India.”
Expanding Treatment Options
Dr. Reddy’s Laboratories, the brainchild of billionaires Satish Reddy and G. V. Prasad, has also launched Obeda, an injectable drug for managing type 2 diabetes, priced at INR4,200 per month. In addition to Obeda, the firm plans to create an integrated care ecosystem including metabolic centres aimed at enhancing diabetes treatment and associated metabolic conditions.
Erez Israeli, CEO of Dr. Reddy’s, expressed that Obeda reinforces the company’s vision of “ensuring advanced diabetes treatments are not only accessible but affordable.”
Similarly, Torrent Pharmaceuticals, led by billionaire brothers Sudhir Mehta and Samir Mehta, has introduced both injectable and oral weight-loss drugs under the Sembolic and Semalix brands, priced at INR3,999 per month.
CEO Amal Kelshikar said, “Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices.”
The Market Landscape
A study conducted in 2023 by the Indian Council of Medical Research revealed that over 100 million people in India have diabetes, and the World Health Organization estimates that approximately 8% of the population is obese.
These companies are part of a larger group of at least eight significant pharmaceutical manufacturers that have introduced semaglutide copies. The market has quickly become competitive, with research firms estimating that up to 40 companies could eventually enter the segment.
As a result, a price war is predicted, with analysts projecting that intense price competition could reduce the cost of some weight-loss drugs in India by up to 90%. Investment bank Jefferies referred to the development as a “magic pill moment” for India, predicting the market could grow to $1 billion.
India, often referred to as the “pharmacy of the world,” is now emerging as a crucial low-cost supplier in the global fight against obesity, much like its past role in reducing the cost of HIV treatments and expanding access worldwide.
Regulatory Oversight
The increase in new product launches has led to heightened scrutiny from regulatory bodies. Concerns have been raised about the availability of generic versions of weight-loss drugs through various channels, such as retail pharmacies, online platforms, wholesalers, and wellness clinics.
The Ministry of Health in India has cautioned that these drugs, when used without proper medical supervision, could potentially lead to serious adverse effects and related health risks. The ministry has also imposed restrictions on marketing such drugs, banning indirect promotional activities that could mislead consumers or promote off-label usage.
There are concerns that patients may view these weight-loss drugs as a “magic pill” solution and may rely on them indefinitely. Mumbai-based diabetologist Rahul Baxi cautioned that these medications are not a substitute for a proper diet or lifestyle change.
Questions & Answers
What is the price of the new weight-loss medications?
Noveltreat is priced at approximately INR3,600 (US$38.3) a month, while Sematrinity costs INR3,000 a month. Obeda, a diabetes medication, is priced at INR4,200 a month.
Is there a predicted price war in the pharmaceutical industry?
Yes, analysts project intense price competition could decrease the cost of some weight-loss drugs in India by up to 90%.
What are the concerns raised by the Ministry of Health in India?
The Ministry of Health has raised concerns about the availability of generic weight-loss drugs without proper medical supervision, which could potentially lead to serious adverse effects and health risks. It has also expressed worry about potentially misleading or indirect promotional activities for these drugs.